- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3: How Payers are assessing the Value of New Agents
Dr. Chernew asks the panelists how payers address the value of these costly combination therapies when there are less expensive options available. Dr. Newcomer says that the drugs being discussed are, in fact, having a significant clinical effect.
Dr. Chernew asks the panelists how payers address the value of these costly combination therapies when there are less expensive options available. Dr. Newcomer says that the drugs being discussed are, in fact, having a significant clinical effect. The combination impacts survival and how long the tumor stays away, which is a real value.
Dr. Chernew asks how payers and financing will impede the access to patients who might benefit from the new agents and Dr. Swain replies, “ I think it will affect them greatly, because what we are already seeing is the patients are coming to hospital settings, who are on Medicare and are not being treated in their doctor’s office and their infusion center because the doctors can’t afford to do it, they actually lose money, so they are coming to a higher price facility, a hospital, to get their infusion. So I think it is really going to affect, not on the patients but the economy in general.”
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
